{"id":"tp-48534","type":"article-newspaper","title":"Peptide boom exposes evidence gaps as drug development and prescribing markets draw interest","author":"John Kim","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/insights/48534","datePublished":"2026-11-04T14:01:44.000Z","dateModified":"2026-11-04T14:01:44.000Z","language":"en","abstract":"Tirzepatide sales reached nearly $44 billion in the first nine months of 2026. Andreessen Horowitz examines evidence gaps in unapproved peptides and prospects for regulated drugs and prescribing businesses.","section":"Insights & Views","references":[]}